Skip to main content
. 2014 Mar 25;9(3):e93050. doi: 10.1371/journal.pone.0093050

Figure 1. The effect of the ARBs telmisartan, valsartan, losartan and candesartan on the proliferation of endometrial cancer cell lines in vitro.

Figure 1

Anticancer effects of telmisartan via the PPARγ-dependent pathway. (A–D) Ishikawa, HEC-59, and HHUA endometrial cancer cell lines were treated with telmisartan, candesartan, losartan or valsartan at various concentrations (1–100 μM) or the vehicle (control) for 48 h, and proliferation (% of control) was measured in a WST-1 assay. Results are means ± SD of three independent experiments with triplicate dishes. *P<0.05 vs. control, **P<0.01 vs. control. (E) Effect of GW9662 on telmisartan inhibition of HHUA cell proliferation. HHUA cells were incubated with telmisartan (10 or 50 μM) for 48 h followed by preincubation with GW9662 (10 μM) for 30 min. We found that the addition of GW9662 inhibited the anticancer effects of telmisartan at 10 or 50 μM. Results represent the means ± SD of three independent experiments. Columns, means; bars, SDs. *P<0.05 vs. control, **P<0.01 vs. control.